SEC Info - Applied Dna Sciences Inc.

SEC Info℠

Home

Help

Please Sign In

Applied Dna Sciences Inc. – ‘8-K’ for 9/22/22

On: Friday, 9/23/22, at 4:06pm ET · For: 9/22/22 · Accession #: 1104659-22-102670 · File #: 1-36745

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 9/23/22  Applied Dna Sciences Inc.         8-K:5       9/22/22   10:192K                                   Toppan Merrill/FA

Current Report — Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     32K 
 5: R1          Cover                                               HTML     45K 
 8: XML         IDEA XML File -- Filing Summary                      XML     11K 
 6: XML         XBRL Instance -- tm2226575d1_8k_htm                  XML     14K 
 7: EXCEL       IDEA Workbook of Financial Reports                  XLSX      8K 
 3: EX-101.LAB  XBRL Labels -- apdn-20220922_lab                     XML     96K 
 4: EX-101.PRE  XBRL Presentations -- apdn-20220922_pre              XML     64K 
 2: EX-101.SCH  XBRL Schema -- apdn-20220922                         XSD     12K 
 9: JSON        XBRL Instance as JSON Data -- MetaLinks               25±    32K 
10: ZIP         XBRL Zipped Folder -- 0001104659-22-102670-xbrl      Zip     15K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX: C: C: C: C: C: C: C: C:

i 0000744452 i false 0000744452 2022-09-22 2022-09-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM i 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): i September 22, 2022

i Applied DNA Sciences, Inc.

(Exact name of registrant as specified in its charter)

i Delaware

(State or other jurisdiction

of incorporation)

i 001-36745

(Commission File Number)

i 59-2262718

(IRS Employer

Identification No.)

i 50 Health Sciences Drive

i Stony Brook, i New York i 11790

(Address of principal executive offices; zip code)

Registrant’s telephone number, including area code:

i 631- i 240-8800

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

i ¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

i ¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

i ¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

i ¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company i ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
i Common Stock, $0.001 par value		i APDN		The i Nasdaq Stock Market

Item 5.07 Submission of Matters to a Vote of Security Holders.

On September 22, 2022, Applied DNA Sciences, Inc. (the “Company”) held its 2022 annual meeting of stockholders (the “2022 Annual Meeting”). The following proposals were voted on and were approved by the Company’s stockholders, except with respect to proposal 2 which was not approved, at the 2022 Annual Meeting with the stockholders having voted as set forth below:

I. To elect seven directors to serve until the 2023 annual meeting of stockholders or until their respective successors are duly elected and qualified.

	FOR	WITHHELD	BROKER NON-VOTES
James A. Hayward	1,613,361	375,993	2,773,010
Robert B. Catell	1,615,523	373,831	2,773,010
Joseph D. Ceccoli	1,621,939	367,415	2,773,010
Scott L. Anchin	1,614,389	374,965	2,773,010
Yacov A. Shamash	1,527,522	461,832	2,773,010
Sanford R. Simon	1,609,331	380,023	2,773,010
Elizabeth M. Schmalz	1,600,880	388,474	2,773,010

II. To grant the board of directors of the Company the discretionary authority to amend the Company’s certificate of incorporation, as amended, to effect a reverse stock split of the Company’s common stock and to reduce the number of authorized shares of the Company’s common stock to 50,000,000.

FOR		AGAINST		ABSTAIN
3,639,252		1,093,517		29,595

III. To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers.

FOR		AGAINST		ABSTAIN		BROKER NON-VOTES
1,386,134		524,487		78,733		2,773,010

IV. To ratify the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending September 30, 2022.

FOR		AGAINST		ABSTAIN
4,516,454		82,725		163,185

Each of the foregoing voting results from the 2022 Annual Meeting is final.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 23, 2022	APPLIED DNA SCIENCES, INC.

	By:	/s/ *James A. Hayward*
	Name:	James A. Hayward

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

	9/30/22
Filed on:	9/23/22
For Period end:	9/22/22	DEF 14A, PRE 14A
		List all Filings

↑Top

Filing Submission 0001104659-22-102670 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)